MREO

Mereo Biopharma Group Plc (MREO) - Q2 2024 10-Q Summary

Business Context and Reporting Period

Mereo Biopharma Group Plc is a UK-based biopharmaceutical company focused on developing therapeutics for rare diseases. The primary product candidates are setrusumab for osteogenesis imperfecta (OI) and alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). This report covers the quarterly period ended June 30, 2024. The company is classified as a non-accelerated filer and an emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Revenue was $0 for the three and six months ended June 30, 2024, compared to $9.0 million in the same periods in 2023. The 2023 revenue was driven by a one-time milestone payment from Ultragenyx for setrusumab.
• Net Loss: Net loss increased significantly to $12.3 million for Q2 2024 from $1.8 million in Q2 2023. For the six-month period, the loss widened to $21.2 million from $13.8 million.
• Operating Expenses: General and Administrative (G&A) expenses surged 195% in Q2 2024 ($7.9 million vs. $2.7 million) and 51% YTD ($13.8 million vs. $9.1 million). This increase is attributed to pre-commercial activities for setrusumab in Europe and a reduction in reimbursements from the company's depository.
• R&D Expenses: Q2 R&D expenses increased 33% to $4.9 million, driven by increased spending on alvelestat (Phase 3 preparation) and setrusumab. YTD R&D expenses remained relatively flat at $8.9 million, as increases in alvelestat and setrusumab were offset by a significant reduction in etigilimab expenses due to the winding down of its clinical study.
• Financing Activity: In June 2024, the company completed an underwritten registered direct offering, raising net proceeds of $47.0 million. This significantly improved liquidity compared to the prior year.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects cash and cash equivalents of $87.4 million as of June 30, 2024, to be sufficient to fund operations and capital expenditure requirements for at least twelve months from the filing date. The company anticipates its resources will extend into 2027 under the current business plan.
• Clinical Progress: On June 11, 2024, Mereo and Ultragenyx announced positive 14-month results from the Phase 2 portion of the Orbit study for setrusumab, showing a sustained 67% reduction in the annualized fracture rate.
• Risks and Contingencies:
  • The company has no approved products and expects to continue incurring losses for the foreseeable future.
  • Future funding requirements depend on the success of clinical trials, regulatory approvals, and potential commercialization.
  • There is a contingent liability related to the Novartis Loan Note due in February 2025, which the company assumes will be converted or refinanced.
  • Significant milestone and royalty payments are due to AstraZeneca and Novartis upon future commercial success.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $87.4 million cash balance against the projected burn rate, considering the increased G&A spend for pre-commercial activities.
• Debt Maturity: Confirm the status and refinancing plans for the $4.9 million convertible loan note due in February 2025.
• Revenue Recognition: Note the absence of revenue in 2024 compared to the one-time $9.0 million milestone in 2023; future revenue is contingent on clinical milestones or product sales.
• Equity Dilution: Review the impact of the June 2024 offering (62.7 million ordinary shares issued) and outstanding options/warrants on future dilution.
• Contractual Obligations: Assess the potential financial impact of future milestone payments to AstraZeneca (up to $115.5 million) and royalties to Novartis.